SGLT2-Is and MRAs combo associated with lower albuminuria in patients with type 2 DM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-01-20 14:30 GMT | Update On 2023-01-21 09:59 GMT

Combination therapy with SGLT2-Is and MRAs is associated with lower albuminuria in patients with type 2 DM compared to monotherapy with SGLT2-Is or MRAs alone suggests a new study published in Diabetes, Obesity and Metabolism

Diabetes mellitus (DM) is the leading cause of chronic kidney disease. Albuminuria is associated with an increased risk of cardiovascular mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) and mineralocorticoid receptor antagonists (MRAs) protect against albuminuria; however, their combined effects on albuminuria are unclear. We performed a network meta-analysis to investigate the effects of SGLT2-Is, MRAs, and their combination on albuminuria in type 2 DM.

They systematically searched PubMed, Medline, EMBASE, and the Cochrane Library from inception up to November 20, 2022. We selected randomized control and crossover trials that compared MRAs, SGLT2-Is, MRAs + SGLT2-Is, or a placebo in patients with type 2 DM with a urinary albumin-creatinine ratio (UACR) ≥ 30 mg/g creatinine. The primary outcome was the change in the UACR.

Results

• This meta-analysis analyzed 17 studies with 34,412 patients.

• The use of combination treatment with SGLT2-Is and MRAs was associated with lower albuminuria compared to the use of SGLT2-Is, MRAs, or the placebo alone

• Treatment with SGLT2-Is or MRAs alone caused a significant reduction in UACR compared to the placebo

• The effects of MRAs on the UACR are comparable to those of SGLT2-Is. Sensitivity analyses showed similar results.

Combination therapy with SGLT2-Is and MRAs was associated with lower albuminuria in patients with type 2 DM compared to monotherapy with SGLT2-Is or MRAs alone.

Reference:

Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M.E., Azushima, K., Wakui, H. and Tamura, K. (2023), Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients. Diabetes Obes Metab. Accepted Author Manuscript. https://doi.org/10.1111/dom.14976

Keywords:

Diabetes, Obesity and Metabolism, Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M.E., Azushima, K., Wakui, H. and Tamura, K, Effects, sodium-glucose, cotransporter 2 inhibitors, mineralocorticoid, receptor antagonists, combination, albuminuria, diabetic patients.

Article Source : Diabetes, Obesity and Metabolism

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SGLT2-Is and MRAs combo associated with lower albuminuria in patients with type 2 DM

Similar News

GLP-1 Drugs Cut Heart Risks in Overweight Diabetics, Safeguard Kidneys for All: JAMA

Ambient Air Pollution Increases Risk of Adverse Outcomes in Kidney Transplant Recipients: Study

Inflammation Markers Help Predict AKI After Bladder Cancer Surgery, reports study

GLP-1RAs Show Promise for Kidney Protection in Type 2 Diabetes, Reveals Research

TAVR Outcomes in ESRD Patients Remain Poor, Large Study Shows

Pneumococcal Vaccination in Hematological Malignancies (HM)-Indian Hematology Expert Consensus 2025

High Uric Acid at ICU Admission Signals Higher Risk of Kidney Complications and Mortality: Study

Pregnancy-Related Acute Kidney Injury Linked to 52-Fold Higher Risk of Serious Renal Complications: Meta-Analysis